Healthcare providers are a trusted resource for cancer patients. The Young Lung Cancer Study aims to better understand lung cancer that occurs in young adults, including somatic and germline genomic changes. We hope that you will encourage your patients diagnosed with NSCLC or SCLC at age 45 and younger to enroll in the Young Lung Cancer Study to help us improve care for this population.
Clinical resources
Our study team is happy to discuss appropriate follow-up testing and other resources for your patient’s management and care. Please contact us if you would like to review any patient cases and resources available.
Eligible patients
Your patients may be eligible to participate in the Young Lung Cancer Study if a patient was diagnosed with NSCLC or SCLC at the age of 45 or younger.
Study goals
Recent data shows that the overwhelming majority of NSCLC diagnosed at age 40 and younger occurs without significant tobacco exposure and contains a targetable genomic alteration. In the Young Lung Cancer study, we aim to understand why this occurs and to investigate possible germline predisposition. This study includes both NSCLC and SCLC.
Our goals are to learn more about the biology of lung cancer occurring in young patients, including somatic and germline genomics; how to better predict cancer risk for young people; and whether future patients would benefit from lung cancer screening.
To achieve these goals, we need to enroll as many patients diagnosed with lung cancer at 45 and younger as possible. If your patients request your help with obtaining their pertinent medical records, or paraffin or blood specimens for the study, please help if you can. Contact our study staff for assistance.
How to refer patients
Please share our website with your patients or contact us using the information below.
Questions?
If you have any questions about the study, please reach out to the Young Lung Cancer Study team at our primary site:
Young Lung Cancer Study team
younglungstudy@dfci.harvard.edu
617-632-4795
